Unity Biotechnology price target lowered to $8 from $10 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Unity Biotechnology to $8 from $10 and keeps a Buy rating on the shares. The firm cites model adjustments for the target drop. The analyst maintains the view that Unity’s novel senolytic small molecule Bcl-xL inhibitor foselutoclax can potentially offer patients disease modifying benefit in the treatment of diabetic macular edema.